Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2024-04-22
Target enrollment:
Participant gender:
Summary
This study is designed to observe and evaluate the safety and the efficacy of the
anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of
Gemcitabine PLUS Cisplatin in patients who were advanced intrahepatic cholangiocarcinoma with
no chance for primary surgery.